InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (5 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
5
T+90 hit rate
30%
T+90 mean return
-18.0%
Across 10 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Weinberg Uri, Directeur Scientifique. Insider active across 1 company, notably NovoCure Ltd. In total, 16 disclosures have been published. Split: 0 buy · 5 sells. Total volume traded: €518k. History available since 10 May 2021. The latest transaction was disclosed on 3 March 2026 (Attribution). Regulator: SEC (Form 4). All data is free.
Declarations16 total
50,125 shares0Ordinary SharesSEC:0001811030-26-000003:0
7,461 shares@ US$13.8395Ordinary SharesSEC:0001811030-26-000002:0
54,975 shares@ US$18.1932.1% of flowOrdinary SharesSEC:0001562180-25-002160:0
268 shares@ US$18.92170.2% of flowOrdinary SharesSEC:0001562180-25-001977:0
4,326 shares@ US$18.78272.6% of flowOrdinary SharesSEC:0001562180-25-001917:0
4,326 shares@ US$18.78272.6% of flowOrdinary SharesSEC:0001562180-25-001837:0
81,799 shares@ US$16.3041.4% of flowOrdinary SharesSEC:0001562180-24-001986:0
305 shares@ US$35.280.3% of flowOrdinary SharesSEC:0001562180-23-005762:0
28,830 shares0Ordinary SharesSEC:0001562180-23-002494:0
12,992 shares0Ordinary SharesSEC:0001645113-23-000029:0
2,379 shares@ US$120.009.1% of flowOrdinary SharesSEC:0001645113-23-000010:0
281 shares@ US$59.0750.5% of flowOrdinary SharesSEC:0001645113-22-000066:0
17,371 shares0Ordinary SharesSEC:0001645113-22-000021:0
35 shares@ US$63.8180.0001% mcap0.6% of flowOrdinary SharesSEC:0001645113-22-000008:0
113 shares@ US$137.1220.0009% mcap4.0% of flowOrdinary SharesSEC:0001645113-21-000089:0
3,846 shares@ US$47.560.010% mcap45.5% of flowOrdinary SharesSEC:0001645113-21-000066:0
16 of 16 declarations
About Weinberg Uri
Uri Weinberg is the Chief Science Officer of NovoCure Ltd. In this role, he is responsible for leading the company's scientific and research initiatives. His expertise in biomedical sciences is essential for the development of new therapies and for innovation within the organization.
